TransMedics Group (TMDX) Reports In-Line Q1 EPS

TransMedics Group (NASDAQ: TMDX) reported Q1 EPS of ($0.29), in-line with the analyst estimate of ($0.29). Revenue for the quarter came in at $7.05 million versus the consensus estimate of $7.1 million.

Recent Highlights

• Net revenue of $7.1 million in the first quarter of 2021, representing a 6% decrease compared to the first quarter of 2020
• Reported U.S. net revenue growth of 11% year-over-year
• Announced positive FDA advisory committee vote for OCS Heart System
• Appointed Stephanie Lovell to Board of Directors
• Announced expectation for mid-July 2021 OCS Liver FDA advisory committee meeting

"We are pleased with our progress as we advance quickly toward several near term regulatory and commercial catalysts expected in 2021," said Waleed Hassanein, MD, President and Chief Executive Officer. "Following the favorable FDA advisory panel vote for OCS Heart, we are working with FDA to map out the process to a decision on our PMA. In addition, we are making significant progress towards our key 2021 catalysts and strategic initiatives, which gives us confidence in our long-term outlook."

For earnings history and earnings-related data on TransMedics Group (TMDX) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Guardian Pharmacy names new COO and CFO, effective July 2026
• Gil Issachar steps down as CTO at Firefly Neuroscience